Vertex (VRTX) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Vertex, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track VRTX live on Mooboard →

31–90 days2

  • Sep 17, 2026
    Vertex(VRTX)Phase 2/3 readout
    Biological/Vaccine · Phase 3 · Type 1 Diabetes; Kidney Transplant
    NCT06832410: An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant. Primary completion 2026-09-17 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 30, 2026
    Vertex(VRTX)Phase 2/3 readout
    VX-121/TEZ/D-IVA · Phase 3 · Cystic Fibrosis
    NCT05444257: A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy. Primary completion 2026-10-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

Later21

  • Dec 30, 2026
    Vertex(VRTX)Phase 2/3 readout
    Inaxaplin · Phase 2 · Proteinuric Kidney Disease
    NCT06794996: Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities. Primary completion 2026-12-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 25, 2027
    Vertex(VRTX)Phase 2/3 readout
    Suzetrigine · Phase 3 · Diabetic Peripheral Neuropathic Pain
    NCT06696443: Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN). Primary completion 2027-01-25 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 2, 2027
    Vertex(VRTX)Phase 2/3 readout
    VX-670 · Phase 1 / Phase 2 · Myotonic Dystrophy Type 1 (DM1)
    NCT06185764: A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1). Primary completion 2027-02-02 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 12, 2027
    Vertex(VRTX)Phase 2/3 readout
    VX-264 · Phase 1 / Phase 2 · Type 1 Diabetes
    NCT05791201: A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes. Primary completion 2027-03-12 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 25, 2027
    Vertex(VRTX)Phase 2/3 readout
    VX-993 · Phase 2 · Diabetic Peripheral Neuropathic Pain
    NCT06619860: Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy. Primary completion 2027-03-25 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 6, 2027
    Vertex(VRTX)Phase 2/3 readout
    Suzetrigine · Phase 3 · Diabetic Peripheral Neuropathic Pain
    NCT07231419: Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy. Primary completion 2027-04-06 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 6, 2027
    Vertex(VRTX)Phase 2/3 readout
    ELX/TEZ/IVA · Phase 3 · Cystic Fibrosis
    NCT05331183: Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del. Primary completion 2027-04-06 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • May 31, 2027
    Vertex(VRTX)Phase 2/3 readout
    Suzetrigine · Phase 3 · Diabetic Peripheral Neuropathic Pain
    NCT06628908: Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy. Primary completion 2027-05-31 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 6, 2027
    Vertex(VRTX)Phase 2/3 readout
    CTX001 · Phase 3 · Sickle Cell Disease; Hydroxyurea Failure
    NCT05329649: Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD). Primary completion 2027-06-06 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 9, 2027
    Vertex(VRTX)Phase 2/3 readout
    CTX001 · Phase 3 · Beta-Thalassemia; Thalassemia
    NCT05477563: Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease. Primary completion 2027-06-09 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 30, 2027
    Vertex(VRTX)Phase 2/3 readout
    VX-880 · Phase 3 · Diabetes Mellitus, Type 1; Impaired Hypoglycemic Awareness
    NCT04786262: A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes. Primary completion 2027-06-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 22, 2027
    Vertex(VRTX)Phase 2/3 readout
    VX-407 · Phase 2 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    NCT07161037: Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW). Primary completion 2027-07-22 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 30, 2027
    Vertex(VRTX)Phase 2/3 readout
    ELX/TEZ/IVA · Phase 3 · Cystic Fibrosis
    NCT06460506: Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older. Primary completion 2027-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 14, 2027
    Vertex(VRTX)Phase 2/3 readout
    CTX001 · Phase 3 · Beta-Thalassemia; Thalassemia
    NCT05356195: Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT). Primary completion 2027-11-14 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 2, 2028
    Vertex(VRTX)Phase 2/3 readout
    VX-147 · Phase 2 / Phase 3 · Proteinuric Kidney Disease
    NCT05312879: Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease. Primary completion 2028-06-02 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 29, 2028
    Vertex(VRTX)Phase 2/3 readout
    Povetacicept · Phase 2 / Phase 3 · Primary Membranous Nephropathy
    NCT07204275: Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN). Primary completion 2028-12-29 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 30, 2029
    Vertex(VRTX)Phase 2/3 readout
    VX-670 · Phase 2 · Myotonic Dystrophy Type 1 (DM1)
    NCT06926621: A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I. Primary completion 2029-01-30 (estimated); status ENROLLING_BY_INVITATION.
    ClinicalTrials.gov ↗
  • Mar 2, 2029
    Vertex(VRTX)Phase 2/3 readout
    Povetacicept · Phase 2 · Myasthenia Gravis, Generalized
    NCT07501702: A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis. Primary completion 2029-03-02 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 30, 2029
    Vertex(VRTX)Phase 2/3 readout
    VNZ/TEZ/D-IVA · Phase 3 · Cystic Fibrosis
    NCT05844449: Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older. Primary completion 2029-07-30 (estimated); status ENROLLING_BY_INVITATION.
    ClinicalTrials.gov ↗
  • Jun 30, 2030
    Vertex(VRTX)Phase 2/3 readout
    VX-121/TEZ/D-IVA · Phase 3 · Cystic Fibrosis
    NCT05422222: Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age. Primary completion 2030-06-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 30, 2039
    Vertex(VRTX)Phase 2/3 readout
    CTX001 · Phase 3 · Beta-Thalassemia; Thalassemia
    NCT04208529: A Long-term Follow-up Study in Participants Who Received CTX001. Primary completion 2039-09-30 (estimated); status ENROLLING_BY_INVITATION.
    ClinicalTrials.gov ↗

How Vertex has moved — past-year price reactions

How binary is VRTX? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

1%
typical day (1Y)
0
±10% days
27.7%
annualized vol
250
trading days
Largest single-day moves
  • +8.3%2026-03-10no matched headline
  • +6.9%2025-12-03no matched headline
  • +6%2026-07-02no matched headline
  • +5.7%2026-02-13no matched headline
  • -4.6%2026-07-08no matched headline
  • -4.6%2026-03-27no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

Vertex — active clinical pipeline

Vertex's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

19 assets23 programsPh1 5Ph2 7Ph3 10· 1 post-marketing (Ph4)
AreasAutoimmuneMetabolicNeuroscienceRare / GeneticOther
CTX001Rare / Genetic · BCL11A
Phase 3
Beta-Thalassemia (3)Sickle Cell Disease
PovetaciceptAutoimmune
Phase 2
Myasthenia Gravis, Generalized
Phase 3
Primary Membranous Nephropathy
SuzetrigineNeuroscience
Phase 1
Pain (2)
Phase 3
Diabetic Peripheral Neuropathic Pain (3)
Biological/VaccineMetabolic
Phase 3
Type 1 Diabetes
ELX/TEZ/IVARare / Genetic
Phase 3
Cystic Fibrosis (2)
VNZ/TEZ/D-IVARare / Genetic
Phase 3
Cystic Fibrosis
VX-121/TEZ/D-IVARare / Genetic
Phase 3
Cystic Fibrosis (2)
VX-147Other
Phase 3
Proteinuric Kidney Disease
VX-880Metabolic
Phase 3
Diabetes Mellitus, Type 1
InaxaplinOther
Phase 2
Proteinuric Kidney Disease
VX-264Metabolic
Phase 2
Type 1 Diabetes
VX-407Other
Phase 2
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
VX-522 mRNA therapyRare / Genetic
Phase 2
Cystic Fibrosis
VX-670Other
Phase 2
Myotonic Dystrophy Type 1 (DM1) (2)
VX-993Neuroscience
Phase 2
Diabetic Peripheral Neuropathic Pain
VX-272Rare / Genetic
Phase 1
Cystic Fibrosis
VX-433Neuroscience
Phase 1
Narcolepsy Type 1 (NT1)
VX-581Rare / Genetic
Phase 1
Cystic Fibrosis
VX-828Rare / Genetic
Phase 1
Cystic Fibrosis

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

See the full biopharma catalyst calendar across all covered companies.